Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.51 |
| ▸ | RAF1 | P04049 | 13/20 | 0.50 |
| ▸ | BRAF | P15056 | 12/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15070776 | 0.90 | RAF1 (0.49) | RAF1BRAF | |
| SCHEMBL15074587 | 0.88 | PLAU (0.57) | PLAUMAPK14RAF1BRAFMAPK13 | |
| SCHEMBL4781325 | 0.81 | RAF1 (0.55) | RAF1BRAF | |
| SCHEMBL4409138 | 0.81 | MAPK14 (0.50) | PLAUMAPK14RAF1BRAFMAPK13 | |
| SCHEMBL4727385 | 0.80 | RAF1 (0.56) | MAPK14RAF1BRAF | |
| SCHEMBL4409060 | 0.79 | MAPK14 (0.54) | PLAUMAPK14RAF1BRAFMAPK13 | |
| SCHEMBL5593159 | 0.79 | RAF1 (0.51) | PLAUMAPK14RAF1BRAF | |
| SCHEMBL4552259 | 0.79 | MAPK14 (0.48) | PLAUMAPK14RAF1BRAFMAPK13 | |
| SCHEMBL5623710 | 0.78 | RAF1 (0.50) | PLAURAF1BRAF | |
| SCHEMBL4727498 | 0.78 | RAF1 (0.53) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | PLAU 4731/4885MAPK14 1291/4885RAF1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.